Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.

AUTOR(ES)

Hellström, I

RESUMO

Mouse monoclonal antibody L6 (IgG2a subtype) recognizes a ganglioside antigen expressed at the surface of cells from human non-small-cell lung carcinomas, breast carcinomas, and colon carcinomas. We now show that this antibody can lyse L6 antigen-positive human tumor cells in the presence of Leu-11b-positive human lymphocytes (i.e., mediate antibody-dependent cellular cytotoxicity) or human serum (mediate complement-dependent cytotoxicity) and that it can inhibit the outgrowth of an L6 antigen-positive human tumor transplanted onto nude mice.

Documentos Relacionados

• Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
• IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
• In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
• The anti-IRBP IgG1 and IgG2a response does not correlate with susceptibility to experimental autoimmune uveitis
• Monomeric IgG2a promotes maturation of bone-marrow macrophages and expression of the mannose receptor.